The OCAI (Oncoimmunology, Congenital Anaemia and Inflammation) research group, led by Dr. Ana Belén Pérez, together with teams from the Netherlands and France, is part of a European research project. This project, called NANEMIAR, aims to find new therapies for patients diagnosed with congenital anaemias, such as thalassaemia.

This initiative was presented by members of the group on 29 March at the I Conference on Patients with Congenital Anaemias. This conference was held in Murcia and, in it, the researchers explained the different goals of the research project for patients affected by these diseases, as well as the trials being carried out in the laboratory.

People affected by congenital anaemia do not have an effective treatment for this disease, but must receive regular transfusions. The aim of the Nanemiar project is to find a therapy that will help improve the quality of life of these patients and, among other things, lengthen the time between bloof transfusions.

Link: https://www.laopiniondemurcia.es/comunidad/2023/05/28/nanoparticulas-tratar-pacientes-anemia-congenita-87973752.html